SGR-1505 (MALT1 inhibitor)
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
SGR-1505 is a MALT1 inhibitor from Schrodinger. It is being developed for mature B-cell neoplasms. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT05544019. The AI role named in the source is molecule discovery. Registry records: NCT05544019, Phase 1, recruiting, updated Feb 13, 2026. About the company, based in United States: Physics-based computational chemistry platform combined with machine learning, sold as software and used for partnered and internal discovery; launched the Bunsen agentic AI co-scientist in 2026. The latest dated source is from Feb 13, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Schrodinger
- Indication
- Mature B-cell neoplasms
- Therapeutic area
- Oncology
- AI role
- Molecule discovery
- Phase in the source
- Phase 1, as of Feb 13, 2026
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Paper
“including combining free energy calculations with machine learning methods and a chemistry-aware compound enumeration workflow”
Source: paper (opens in new tab)
Trial records
- NCT05544019 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
NCT05544019 first posted on ClinicalTrials.gov
-
ClinicalTrials.gov record: Phase 1
-
NCT05544019 record updated
Phase 1, Recruiting
About Schrodinger
Physics-based computational chemistry platform combined with machine learning, sold as software and used for partnered and internal discovery; launched the Bunsen agentic AI co-scientist in 2026.
Spot an error? Tell me and I'll fix it.